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Purpose. To determine associations between mediators in tears in the whole spectrum of keratoconus (KC); to explore connections
between mediators and Scheimpflug parameters; to examine correlations between Scheimpflug parameters and bronchial asthma.
Methods. Tear samples were collected from 69 patients and 19 controls. Concentrations of mediators—IL-6, -10; CXCL8, CCL5;
MMP-9, -13; TIMP-1; t-PA, PAI-1—weremeasured by Cytometric Bead Array.Measured Pentacam parameters include keratometry
values (𝐾
1
, 𝐾
2
, 𝐾max), corneal thickness (Pachy Pupil, Apex, Min), and elevations and indices (including Belin-Ambro´sio
deviation (BAD-D)).Results.Anumber of significant positive associationswere observed between pairs ofmediator concentrations.
Significant positive correlations were found between BAD-D and CXCL8/MMP-9 and 𝐾
2
and MMP-9. Significant negative
associations were explored between Pachy Min and CXCL8/t-PA. Significant associations were found between pairs of mediators
(IL-6 andCXCL8; CCL5 andCXCL8/MMP-9; TIMP-1 andMMP-9/-13/t-PA; t-PA andCXCL8/CCL5/PAI-1) and the severity of KC.
Significant positive correlation between asthma and the severity of KCwas explored.Conclusion.Cooperation of differentmediators
in tears all taking part in the complex pathomechanism of keratoconus was revealed. Our research verifies that inflammation plays
a crucial role in the pathogenesis of KC. Additionally this study confirms the effect of bronchial asthma on keratoconus.
1. Introduction
1
Keratoconus (KC) is usually a bilateral, progressive ectatic
corneal disorder, usually appearing in puberty [1–3]. The
corneal stroma becomes thinner and protrudes, causing the
typical conical shape that leads to irregular astigmatism,
myopia, and the decrease of visual acuity [1–3]. The apex of
the protrusion can most commonly be found in inferotem-
poral orientation from the center of the cornea [1, 2]. The
incidence of KC is around 1 : 2,000 in the general population
[2]. The etiology of the disease is not yet known in detail [1–
4].2
Classically, KC is considered to be a noninflammatory
disease [1]. However, recent studies have suggested that
inflammatory factors play a key role in the pathomechanism
of the disorder [4]. Elevated levels of interleukin- (IL-) 1b, IL-
4, IL-5, IL-6, IL-8, and IL-17; tumor necrosis factor (TNF)-𝛼,
-𝛽; interferon- (IFN-) 𝛾; matrix metalloproteinase- (MMP-) 3
1, MMP-3, MMP-7, MMP-9, and MMP-13; Cathepsin B;
and Lipocalin-1 have been found in the tears of patients
with keratoconus [4–11]. Decreased levels of IL-4, IL-10,
IL-12, and IL-13; TNF-𝛼; IFN-𝛾; Chemokine (C-C motif)
ligand 5 (CCL5/RANTES, regulated on activation, normal
T cell expressed and secreted); lipophilin C; lipophilin
A; lactoferrin; 𝛼-fibrinogen; zinc-𝛼2-glycoprotein (ZAG);
immunoglobulin A (IgA); immunoglobulin 𝜅-chain (IGKC);
polymeric immunoglobuline receptor (PIGR; phospholipase
A2; cystatin S; cystatin SN and cystatin SA have also been
found in the tear fluid [4, 8, 10–14]. Kenney et al. have found
a decreased level of tissue inhibitor of metalloproteinase-1
(TIMP-1) in KC corneas, compared to normal corneas [15].
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In addition, an association between KC and bronchial
asthma has been identified almost 50 years earlier [16]. Sev-
eral studies have demonstrated a strong association between
KC, asthma, and other immune disorders, pointing to the
crucial role of the immune system in the pathogenesis of
keratoconus [17, 18].
In the past few decades, slit-imaging technologies pro-
vided further improvement in corneal imaging. Nowadays,
we canmeasure not only the front but also the back surface of
the cornea with pachymetric mapping and can typify corneal
architecture in three dimensions. Furthermore, Ambro´sio et
al. established numerous indices to improve the screening of
the ectasia [19, 20].5
There are only a few preliminary studies examining the
association between mediators (mainly cytokines) in the tear
fluid and the severity of keratoconus. Lema and Dura´n
analyzed 28 eyes [5], Jun et al. checked 18 patients [13], and
Kolozsva´ri et al. studied only 14 keratoconic eyes [21]. In
a recent study, Shetty et al. [22] examined the association
betweenMMP-9, IL-6, TNF-𝛼, and different stages of KC.The
crucial limitations of these studies [5, 13, 21, 22] are the small
number of patients, or the few examined mediators, or the
lack of subclinical cases.
In the present study, our goals were to determine
associations between the different types of mediators in
tear fluid—IL-6, IL-10, chemokine (C-X-C motif) ligand 8
(CXCL8)/IL-8, CCL5/RANTES, MMP-9, MMP-13, TIMP-1,
tissue plasminogen activator (t-PA), and plasminogen activa-
tor inhibitor (PAI-1)—in the whole spectrum of keratoconic
eyes (suspect, subclinical, and manifest cases of kerato-
conus) and normal eyes. An additional goal was to explore
associations between these mediators and the Scheimpflug
parameters which characterize the severity of keratoconus.
Our aim was also to examine the relationship between the
Scheimpflug imaging parameters and bronchial asthma in
keratoconus.
2. Patients and Methods
2.1. Subjects and Clinical Examinations. In this prospective
study, patients with keratoconus and normal subjects were
recruited from the Outpatient Unit, Department of Oph-
thalmology, Faculty of Medicine, University of Debrecen,
Hungary.
We examined patients with keratoconus at all stages
(severe, moderate, and mild KC, subclinical KC or forme
fruste KC) and normal, control patients. We have categorized
the participants based on the clinical stage of keratoconus,
but group allocation was not a factor in the analysis. An
eye was diagnosed as having keratoconus where it had one
or a combination of the following clinical signs: central or
paracentral stromal thinning of the cornea, conical protru-
sion, Fleischer’s ring, Vogt’s striae by slit-lamp examination,
and topographic changes [23]. The stages of KC were divided
between mild, if the steepest keratometric reading (𝐾
2
) was
<45 diopters (D); moderate, when 𝐾
2
was between 45 and
52D; and severe if 𝐾
2
was >52D [13, 24]. At present, there
are no specific or universally accepted criteria categorizing
an eye as having subclinical KC or forme fruste KC (FFKC).
The criteria for diagnosing subclinical KC or FFKC were
defined as one or a combination of the following clinical signs:
if it was the fellow eye of a patient with keratoconus and
had a normal cornea on slit-lamp examination (in several
cases, keratoplasty or corneal cross-linking was performed
on the keratoconic eye), or using a Pentacam, the BAD-
D (Belin-Ambro´sio deviation index) [20], ART Max (Max-
imum Ambro´sio’s Relational Thickness) [19], and PPI Ave
(Average Pachymetric Progression Index) [19]; or where the
back elevation values at the thinnest location (B.Ele.Th.) were
not in the normal range of the Pentacam; or where the criteria
of KC did not apply but the maximum keratometric reading
of the front surface (𝐾max Front) was more than 47D.
We included a randomly selected eye from each partic-
ipant, although both eyes were examined. Eye selection was
based on generating random values usingMicrosoft Excel set
to produce numeric indicators with equal probabilities for
either eye. Altogether, 69 patients (mean (SD) age 30.7 (10.3),
range 13–68 years) with the following diagnoses—severe KC:
25, moderate KC: 21, mild KC: 5 and subclinical KC: 18—and
19 normal controls (mean (SD) age 31.7 (11.5), range 18–67
years) were enrolled in the study. The 69 eyes of the patients
represented the whole spectrum of the abnormal, ectatic, and
keratoconic corneas, although no such group allocation was
made.
The exclusion criteria included the existence of active
inflammatory or infective systemic or ocular disease, eye
rubbing, and current treatment with systemic or local anti-
inflammatory drugs. Those eyes that were affected by pre-
vious ocular surgery or trauma, as well as those patients
who were pregnant or lactating during the course of the
study, were also excluded. Written informed consent from
each participant, as well as permission from the University of
Debrecen Institutional Ethics Committee, was obtained prior
to enrollment. The tenets of the Declaration of Helsinki were
followed in all procedures during the study.
Both eyes of each participant underwent ophthalmo-
logical evaluation, including clinical history (especially
bronchial asthma and contact lens usage), automated kerato-
refractometry (KR-8900; Topcon Co, Tokyo, Japan), uncor-
rected and corrected distance visual acuity determinations,
slit-lamp biomicroscopy (under low illumination to avoid
reflex tearing), Rotating Scheimpflug tomography (Pentacam
HR, Oculus Optikgera¨te GmbH, Wetzlar, Germany), and
nonstimulated tear sample collection with glass capillaries.
2.2. PentacamMeasurements. All eyes were examined with a
Pentacam HR (software version 1.16r26 and 1.17r139) without
the application of any eye drops. Three sequential scans were
taken in each eye by the same trained examiner. In short,
the patients were asked to keep both eyes open and fixate
on the target, in the center of the blue fixation beam. The
examiner with the joystick then focuses and obtains a correct
alignment with the corneal apex and a perfect focus, and
the instrument automatically takes 25 Scheimpflug images
within two seconds. The quality of images was checked
under the quality specification (QS) window and only the
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Table 1: Significant positive associations between the concentrations of the different tear mediators.
IL-6
(pg/mL)
IL-10
(pg/mL)
CXCL8
(pg/mL)
CCL5
(pg/mL)
MMP-9
(ng/mL)
MMP-13
(ng/mL)
TIMP-1
(ng/mL) t-PA (pg/mL)
PAI-1
(ng/mL)
IL-6 (pg/mL) 𝑝 < 0.0001 𝑝 <0.0001∗ 𝑝 < 0.0001 𝑝 = 0.0203
𝑝 <
0.0001∗ 𝑝 < 0.0001
∗ 𝑝 < 0.0001∗ 𝑝 < 0.0001
IL-10 (pg/mL) 𝑝 < 0.0001 𝑝 < 0.0001 𝑝 < 0.0001 𝑝 < 0.0001 𝑝 < 0.0001∗
CXCL8 (pg/mL) 𝑝 < 0.0001 𝑝 < 0.0001 𝑝 < 0.0001 𝑝 < 0.0001 𝑝 < 0.0001∗ 𝑝 < 0.0001
CCL5 (pg/mL) 𝑝 < 0.0001 𝑝 < 0.0001∗ 𝑝 < 0.0001
MMP-9 (ng/mL) 𝑝 < 0.0001 𝑝 < 0.0001
MMP-13 (ng/mL) 𝑝 = 0.0001∗ 𝑝 < 0.0001 𝑝 < 0.0001∗
TIMP-1 (ng/mL) 𝑝 < 0.0001∗ 𝑝 < 0.0001∗
t-PA (pg/mL) 𝑝 < 0.0001∗
PAI-1 (ng/mL)
IL: interleukin; CXCL8: chemokine (C-X-C motif) ligand 8 = IL-8; CCL5: chemokine (C-C motif) ligand 5; RANTES: regulated on activation, normal
T cell expressed and secreted; MMP: matrix metalloproteinase; TIMP-1: tissue inhibitor of metalloproteinase-1; t-PA: tissue plasminogen activator; PAI-1:
plasminogen activator inhibitor (shape of relationship: linear, quadratic∗).
Table 2: Significant associations between tear mediators and Penta-
cam indices.
CXCL8 (pg/mL) MMP-9 (ng/mL) t-PA (pg/mL)
BAD-D 𝑝 = 0.020 𝑝 = 0.005
𝐾
2
F (D) 𝑝 = 0.031
Pachy Min p = 0.027 p = 0.023
BAD-D: Belin-Ambro´sio deviation index; KI: keratoconus Index; 𝐾2: Hol-
laday equivalent keratometry value in the steep meridian on the front
surface; Pachy Min: corneal thickness at the thinnest point of the cornea;
CXCL8: chemokine (C-X-C motif) ligand 8; IL-8: interleukin-8; MMP-9:
matrix metalloproteinase-9; t-PA: tissue plasminogen activator (bold values
represent negative correlations).
correct measurements (“QS” reads “OK”) were accepted; if
the comments were marked yellow or red, the examination
was repeated [25, 26].6
The following parameters were exported to Microsoft
Excel (Microsoft Corp, Redmond, Washington): Holladay
equivalent keratometry values in the flat (𝐾
1
) and steep
(𝐾
2
) meridian; maximal keratometry of the front surface
(𝐾max Front); corneal astigmatism (Astig); corneal thickness
at the pupil’s center (Pachy Pupil), at the apex (Pachy Apex)
and at the thinnest point of the cornea (Pachy Min); Index
of Surface Variation (ISV); Index of Vertical Asymmetry
(IVA); Keratoconus Index (KI); Central Keratoconus Index
(CKI); Index of Height Asymmetry (IHA); Index of Height
Decentration (IHD); front and back elevation at the thinnest
location (F.Ele.Th. and B.Ele.Th.); minimal, maximal, and
average pachymetric progression indices (PPI Min, PPI Max,
and PPI Ave); Ambro´sio’s Relational Thickness (ART); and
Belin-Ambro´sio deviation index (BAD-D).
2.3. Tear Collection and Analysis. Nontraumatic tear collec-
tion was carried out using sterile thin glass microcapillary
tubes from the inferior meniscus, without anesthetic drops
or stimulation. Tears were collected for twominutes and then
promptly transferred to Eppendorf tubes and frozen at −80∘C
without centrifugation, within 15 minutes of collection. The
samples were stored until they were analyzed. In all cases,
the total volume of collected tear samples was registered. We
calculated tear volumes from the length of the tear column in
the tube.
In tear samples, the concentrations of IL-6, IL-10,
CXCL8/IL-8, CCL5/RANTES, MMP-9, MMP-13, TIMP-1, t-
PA, and PAI-1 were measured using the Cytometric Bead
Array method. Combined FlowCytomix Simplex Kits were
used with the suitable FlowCytomix Basic Kit, with minor
modifications to the manufacturer’s orders (eBioscience,
Bender Med Systems GmbH, Vienna, Austria) [27]. Briefly
stated, 12.5 𝜇L of tear samples (diluted samples, if necessary)
or serial dilutions of mixed standard cytokines were added
to a 12.5 𝜇L suspension of fluorescent cytokine capture beads
in multiwell filter microplates. Added to the wells were 12.5
microliters of biotin-conjugated anti-cytokine antibodies,
after which the plates were incubated for two hours on a
microplate shaker.The wells were emptied and washed with a
vacuumfiltrationmanifold. Phycoerythrin-conjugated strep-
tavidin was added to the plate wells, followed by an additional
incubation period of one hour and washed as described
before. A 150𝜇L assay buffer was applied to the wells, after
which multiparametric data acquisition was executed using a
FACS Array cytometer (BD Biosciences Immunocytometry
Systems, San Jose, CA). The data were analyzed with the
FlowCytomix Pro 2.3 software (eBioscience). Additional
serial dilutions of the standard were applied to achieve better
sensitivity andmodified standard curves were thus generated
in the analysis. The subsequent detection limits were as
follows: IL-6: 1.2 pg/mL; IL-10: 1.9 pg/mL; CXCL8 (IL-8):
0.5 pg/mL; CCL5 (RANTES): 25 pg/mL; MMP-9: 95 pg/mL;
MMP-13: 50 pg/mL; TIMP-1: 28 pg/mL; t-PA: 4.8 pg/mL; and
PAI-1: 13.5 pg/mL.
2.4. Statistical Analysis. We categorized the participants for
descriptive purposes based on clinical severity (group allo-
cation was not used as a variable in the analysis). Mediator
concentration variables were inspected for the distribution
shape andnatural log transformed (for t-PA andPAI-1, square
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Table 3: Additive differences in the Standardized Pentacam Score at various locations defined by TIMP-1 concentration (ng/mL) and MMP-
13 concentration (ng/mL) versus the indicated reference point, as estimated by linear regression adjusted for age, the presence of asthma, and
contact lens usage.
TIMP-1 (ng/mL)
MMP-13 (ng/mL)
12.18 20.09 33.12 54.60 90.02 148.41
33.12 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05 Referencepoint
54.60
4.96
[0.27; 9.64]
𝑝 = 0.038
𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05
90.02
4.30
[0.021; 8.59]
𝑝 = 0.049
𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05
148.41 N/A N/A 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05 𝑝 > 0.05
244.69 N/A N/A 𝑝 > 0.05
3.93
[0.084; 7.79]
𝑝 = 0.045
4.60
[0.69; 8.51]
𝑝 = 0.022
4.43
[0.29; 8.58]
𝑝 = 0.037
Square brackets indicate 95% confidence intervals; N/A indicates insufficient sample coverage for estimation.
Table 4: Significant associations between pairs of mediators and the Standardized Pentacam Score.
IL-6 (pg/mL) CCL5 (pg/mL) TIMP-1 (ng/mL) t-PA (pg/mL)
CXCL8 (pg/mL) 𝑝 = 0.014 𝑝 = 0.028 𝑝 = 0.024
CCL5 (pg/mL) 𝑝 = 0.026
MMP-9 (ng/mL) 𝑝 = 0.04 𝑝 = 0.001
MMP-13 (ng/mL) 𝑝 = 0.043
t-PA (pg/mL) 𝑝 = 0.014
PAI-1 (ng/mL) 𝑝 = 0.02
IL: interleukin; CXCL8: chemokine (C-X-C motif) ligand 8 = IL-8; CCL5: chemokine (C-C motif) ligand 5; RANTES: regulated on activation, normal
T cell expressed and secreted; MMP: matrix metalloproteinase; TIMP-1: tissue inhibitor of metalloproteinase-1; t-PA: tissue plasminogen activator; PAI-1:
plasminogen activator inhibitor.
root transformed) to improve normality. Similarly, Pentacam
parameters were subjected to one of these transformations if
that improves distributional symmetry.
Pentacam parameters were unified in a composite index
referred to as the Standardized Pentacam Score. This was
calculated by centering, standardizing, and direction correct-
ing the source variables (so that the higher values invariably
representmore severe pathologies), running a principal com-
ponent analysis and deriving the first principal component.
Associations between all possible pairs of mediator levels,
as well as those between mediators in the tear fluid and
Scheimpflug parameters, were evaluated using simple linear
regression, including a quadratic term by a curvature in
the relationship, if required. Associations between pairs
of mediators and the Standardized Pentacam Score were
assessed using multiple linear regressions adjusted for age,
the presence of asthma, and contact lens usage. Mediator
variables were used in linear and quadratic forms, and inter-
actions between those terms were also included in order to
accommodate the model to curvatures in the outcome space.
Relationships were expressed as the overall significance of the
mediator pair effect and also as additive differences in the
Standardized Pentacam Score at sample-covered locations,
defined by mediator pair concentrations versus an arbitrary
reference point.
3. Results
3.1. Associations between Mediator Levels in the Tear Fluid.
A number of significant positive associations were observed
between pairs of mediator concentrations in tear fluid col-
lected from KC patients and subjects with normal eyes, as
shown in Table 1.
3.2. Associations between Mediators in the Tear Fluid and
Scheimpflug Parameters. Significant positive associations
were found between BAD-D and CXCL8, BAD-D andMMP-
9, and𝐾
2
and MMP-9. Significant negative associations were
found between Pachy Min and CXCL8 and Pachy Min and
t-PA (Table 2).
3.3. Associations between Pairs of Mediators and the Standard-
ized Pentacam Score (A Composite Parameter Calculated from
Pentacam Readings). A significant association was found
between the TIMP-1 concentration, the MMP-9 concentra-
tion, and the Standardized Pentacam Score: the combination
of high TIMP-1 and low MMP-13 levels was characterized by
a low score, while high levels of both mediators—as well as
low TIMP-1 concentrations coupled with moderate MMP-9
levels—were associated with an elevated score (Table 3).
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Significant associations were also found between the
concentrations of a number of other pairs of mediators and
the Standardized Pentacam Score as shown in Table 4.
3.4.The Effect of Bronchial Asthma on Standardized Pentacam
Score. There was a history of asthma in five patients (7.25%)
and one of contact lens usage in 15 patients (21.74%). A strong,
significant positive association between asthma and the
Standardized Pentacam Score was found by linear regression
adjusted for age and contact lens usage. Asthmatic patients’
scores were, on average, an estimated 5.7 units (95% CI: 2.0
to 9.4, 𝑝 = 0.003)—or 1.32 standard deviations—higher than
those of subjects without the condition.
4. Discussion
To the best of our knowledge, this is the first study that
aimed to reveal associations between pairs of mediators and
the severity of keratoconus, evaluated using a Pentacam.
Despite the intensive clinical and biochemical investigations,
the pathogenesis of keratoconus is not yet known in detail.
Classically, keratoconus was considered a noninflammatory
disease [1]; however, recently published articles have sug-
gested that inflammation is involved in the pathogenesis of
KC [4, 7–14]. In the tear fluid of keratoconic patients, elevated
levels of IL-6, TNF-𝛼, and MMP-9 were detected, and IL-6
andTNF-𝛼 levels were also elevated in subclinical cases [5, 6].
Jun et al. found high level of IL-6 and low levels of IL-12, TNF-
𝛼, IFN-𝛾, IL-4, IL-13, andCCL5 in the tear fluid ofKCpatients
[13]. Partly in line with these results, increased tear levels of
MMP-1, MMP-3, MMP-7, MMP-9, and MMP-13; IL-4, IL-5,
IL-6, and IL-8, and TNF-𝛼, -𝛽 were found in keratoconus
[9]. In keratoconic corneas, a decrease in TIMP-1 mRNAwas
reported [15]. Only few studies investigated the associations
between a range of cytokines in the tear fluid and the severity
of keratoconus. The limitations of these reports are the small
number of patients, or the few examined mediators, or the
lack of subclinical cases [5, 13, 21, 22].
In the current study, we have determined the associ-
ations between nine mediators (IL-6, IL-10, CXCL8/IL-8,
CCL5/RANTES, MMP-9, MMP-13, TIMP-1, t-PA, and PAI-
1) in the tear fluid of keratoconic patients covering the
whole spectrum of the disease (from subclinical to manifest
keratoconus). In accordance with earlier studies, we proved
that different mediators—including cytokines, chemokines,
enzymes, and inhibitors—in the tear fluid cooperate and
take part in a complex immunological network [4, 5, 7–
14, 21]. Significant associations were explored between the
concentrations of different mediators (between IL-6 and
CXCL8; between CCL5, CXCL8, and MMP-9; between
TIMP-1, MMP-9, MMP-13, and t-PA; and between t-PA,
CXCL8, CCL5, and PAI-1) and the Standardized Pentacam
Score, which is a composite index statistically unifying all
Pentacam parameters. As far as we know, there are no studies
evaluating the association between different tear mediators
and Pachy Min and also BAD-D, which was designed to
present comprehensive data based on anterior and posterior
corneal elevation and a pachymetric evaluation. Our results
support the linkage between the complex network of the
various mediators and the comprehensive Pentacam indices.
Based on our results, inflammation not only seems to be
involved in the pathogenesis of keratoconus, but also plays
a crucial role in the pathological corneal processes from
the initial stage to the final one. We have found only a
few significant associations between the single mediators
and Pentacam indices, highlighting the fact that mediators,
including cytokines, take part in a complex cascade. The
examined mediators overlap, neutralize and enhance the
effects of one another. It is in line with evidence showing
that variousmultitargetedmediators in the serum collaborate
in different diseases, suggesting that examination of only
one or a few mediators is not enough to explore complex
immunopathological processes [13, 28, 29].
MMPs are zinc-dependent endopeptidases, which partic-
ipate in degrading and remodeling the extracellular matrix,
thereby maintaining its integrity during normal conditions.
Nevertheless, under pathological conditions, MMPs can sup-
port tissue destruction and other inflammatory reactions.
TIMP-1 is the inhibitor of MMPs, which prevents pro-
MMP activation and, furthermore, presents antiapoptotic
properties [15, 30, 31]. MMP-13 was categorically reported in
keratoconus, suggesting that it plays a role in intra- and extra-
cellular pathological collagen destruction [32]. Additionally,
proMMP-13 activation is partially inhibited by TIMP-1 [33].
In line with these studies, we have found significant associ-
ations between TIMP-1 concentration, MMP-13 concentra-
tion, and the Standardized Pentacam Score.The combination
of high TIMP-1 and low MMP-13 levels was characterized by
a low score, while high levels of both mediators—as well as
low TIMP-1 concentrations coupled with moderate MMP-
9 levels—were associated with elevated scores. Additionally,
significant positive associations were found between MMP-9
and BAD-D, and also with 𝐾
2
.
Based on our study and others, the collagenolytic milieu
of the human cornea seems to be more complex than
expected. Further studies are required to understand the
exact mechanisms of collagenases and inhibitors.
An active form of t-PA converts plasminogen to plasmin
and can also degrade several components of the extracellu-
lar matrix, triggering the activation of the MMP pathway.
Numerous interactions have been observed between the
fibrinolytic and MMP systems taking part in proteolytic
activation. Plasminogen activators are partially regulated by
PAIs, inhibiting this cascade system and, therefore, influ-
encing KC progression [34]. Different growth factors and
cytokines induce the PAI-1 gene and inhibit the activity of
the t-PA enzyme. In addition, PAs could affect the proteolytic
inactivation of growth factors [35]. Significant associations
between the severity of keratoconus and pairs of t-PA/TIMP-
1 and t-PA/PAI were detected in our study. In addition to
this observation, significant negative associations were found
between the corneal thickness at the thinnest point of the
cornea and t-PA.
Apart from the elements of the proteolytic andfibrinolytic
systems, we have examined different cytokines, such as the
proinflammatory IL-6 and chemokine CXCL8/IL-8 and the
anti-inflammatory Th2 cytokine IL-10 [13]; we found that
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all of these cytokines cooperate with each other and play
a crucial role in the pathogenesis of KC. The significant
positive association between BAD-D and CXCL8 and the
significant negative correlation between Pachy Min and
CXCL8 highlight the roles of the chemokines.
Bronchial asthma is a chronic airway inflammatory dis-
ease. The infiltration of eosinophils, mastocytes, and T lym-
phocytes and the release of several inflammatory mediators
play an important role in asthma’s pathogenesis [36, 37].
Different proteins are altered in the serum of these patients,
such as IgE; IL-1, IL-4, IL-6, IL-8, and IL-13; CCL5; TNF-𝛼;
MMP-9; TIMP-1; t-PA; and serum Angiopoietin-1 [36, 38–
43]. Due to an increase in the number of known mediators,
additional anti-inflammatory options are becoming available
in the therapy of asthma. The connection between asthma
andother atopic diseaseswith keratoconuswas first published
almost 50 years ago and has been confirmed several times
since then [16–18]. We found a strong significant positive
association between asthma and the severity of keratoconus,
meaning that asthmatic patients have 5.7 higher score than
nonasthmatic subjects. Based on our study, bronchial asthma
has an impact on the severity of keratoconus. This result
albeit was a secondary outcome of our study and confirms
the previous hypothesis related to the connection betweenKC
and asthma. Further larger randomized studies are required
to verify this strong correlation.
The strengths of our study are the large number of par-
ticipants (88 subjects) and the consideration of a wide range
of tear mediators that could be associated with Pentacam
parameters. Our study has limitations, such as the lack of
examination of enzyme activities, as well as the fact that
we did not examine the progression of keratoconus and the
effect of asthma medication. In addition, this study does
not exclude the role of other inflammatory molecules in the
pathophysiology of KC. It would be interesting to measure
more and different types of mediators, but this remains to
be determined in subsequent studies. However, several new
correlations can be revealed from our results that can be the
basis for further study of this topic.
5. Conclusion
Keratoconus has a complex pathomechanism, in whichmany
different cytokines, chemokines, enzymes, and inhibitors are
involved. This study reveals the cooperation of the different
mediators in tear fluid all taking part in this complex
immunological network. As far as we know, this is the first
study to reveal associations between tearmediators andBAD-
D or Pachy Min. Our study confirms that inflammation is
involved in the pathogenesis of keratoconus. As a next step,
the precise role of these mediators needs to be defined, as
well as examination of the progression of KC and exploration
of other mediators’ functions. These studies might then
serve as a platform for finding targets for local inhibition
of pathological corneal thinning, or eventual treatment. In
addition, our study confirms the effect of bronchial asthma
on keratoconus. Further prospective studies are required to
examine the effect of the systemic treatment of asthma on the
pathomechanism of keratoconus.
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